still needs to concentrate on the detection and evaluation of new, robust, and reliable predictive markers for those costly therapies.
Breast cancer (BC) is the most common female cancer and the second leading cause of cancer death in women [1] . BC is an extraordinarily heterogeneous disease, composed of distinct intrinsic subtypes, which may be defined by gene expression profiling or immunohistochemistry biomarkers [2] . After the groundbreaking research data of Perou et al. [3] , we now classify breast cancer into 4 intrinsic subtypes -luminal A and B, HER2 enriched and basal-like. In the last years, extensive research has been done on triple-negative breast cancer. Using gene expression profiling, the triple-negative subgroup was re-classified into 6 subtypes: basal-like 1 and 2, immunomodulatory, mesenchymal, mesenchymal stem-like, and luminal androgen receptor subtype [4] . Those subtypes describe well defined cancer subgroups that differ in molecular, pathological, and prognostic characteristics. In 2000, and updated in 2011, Hanahan and Weinberg [5] postulated 6 hallmarks of cancer and at least 2 emerging hallmarks that are necessary for tumor growth and / or invasion. All those hallmarks include distinct intracellular signaling pathways that are enhanced or blocked during tumor progression. Some of those signaling cascades are well investigated, others are not yet completely understood. Besides a specific signaling pathway from surface receptors to the nucleus in certain tumor subtypes, there are some crosslinks between various pathways, e.g. ER and EGF receptor pathways. Crosslinking can result in enhancement or attenuation of the cell signal leading to therapy resistance and tumor growth. After years of treatment options solely based on endocrine and cytotoxic treatments, targeted and pathway-oriented therapies found their way into clinical practice. This became only possible by an increasing understanding of the molecular details of signaling pathways linked to initiation, invasion, and migration. Understanding the complex mechanisms of intracellular and intranuclear signaling is the key in the development of pathway oriented therapies.
Nonetheless, a persisting major medical need is the detection of predictive markers for those pathway oriented therapies. So far, only the estrogen and HER2 receptors are established and implemented in clinical routine for the identification of patients who will benefit from certain therapies. Therefore, translational research
